Form 4: Relay Therapeutics Director Claire Mazumdar Granted Significant Stock Options

Relay Therapeutics, Inc. Director Claire Mazumdar was granted 421,241 stock options with an exercise price of $3.36, vesting over 36 months.

Summary

• Claire Mazumdar, a Director at Relay Therapeutics, Inc. (RLAY), was granted 421,241 stock options.
• The transaction date for this grant was June 9, 2025.
• The exercise price for these stock options is $3.36 per share.
• The options will vest in thirty-six (36) equal monthly installments starting after June 9, 2025.
• Vesting is contingent upon Ms. Mazumdar's continued service with Relay Therapeutics through each vesting date.
• The stock options have an expiration date of June 8, 2035.
• Following this transaction, Ms. Mazumdar beneficially owns 421,241 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns management's interests with shareholders. It's a routine compensation event, not indicative of major operational changes, hence a moderately positive score.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Relay Therapeutics.
• The substantial number of options granted (421,241) indicates a significant equity incentive for the director's continued commitment to the company.

Risks

• The value of the stock options is subject to the future market price of Relay Therapeutics' common stock, meaning they could become worthless if the stock price falls below the exercise price.
• Vesting of the options is conditional on the reporting person's continued service, posing a risk if service is terminated before full vesting.

Future Outlook

The vesting schedule of 36 equal monthly installments over three years indicates an expectation of continued service from the director, aligning their incentives with the company's long-term strategic goals and performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to attract, retain, and incentivize talent by aligning their interests with long-term shareholder value creation.

Related Party Transactions

• The grant of stock options to Claire Mazumdar, a director, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees (Director): Claire Mazumdar receives significant equity compensation, incentivizing her continued dedication and performance.

Next Steps

• The stock options will vest in 36 equal monthly installments after June 9, 2025, subject to continued service.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Claire Mazumdar, Beneficial Ownership